The approval is based on the RELATIVITY-047 trial, which tested Opdivo + relatlimab against Opdivo monotherapy and had a PFS HR=0.75 (#msg-163914232).
In first-line melanoma, Opdulag offers comparable efficacy to Opdivo + Yervoy with less toxicity.
My abbreviated take:
$BMY's LAG-3 result in first-line melanoma looks like a fairly modest medical advance, but one that will probably make serious money for the company in the coming years. (I'm long.)— Roy Friedman (@DewDiligence) May 19, 2021
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”